Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iopamidol
Drug ID BADD_D01181
Description Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.
Indications and Usage Not Available
Marketing Status approved
ATC Code V08AB04
DrugBank ID DB08947
KEGG ID D01797
MeSH ID D007479
PubChem ID 65492
TTD Drug ID D0O2HQ
NDC Product Code 68225-077; 0270-1412; 68225-078; 68225-100; 0270-1315; 0270-1317; 0270-1411; 70436-126; 62331-006; 0270-1316; 68225-076; 0270-1314; 70436-124; 57876-222
UNII JR13W81H44
Synonyms Iopamidol | Jopamidol | Gastromiro | Iopamidol, (+-)-Isomer | Iopamidol, (R)-Isomer | Iopamidol, Sodium Salt, (S)-Isomer | Iopamiro | Isovue 370 | Niopam | Solutrast | Solutrast 370 | Solutrast Gastro | SQ 13,396 | B-15,000 | B 15,000 | B15,000 | B-15000 | B 15000 | B15000 | Isovue
Chemical Information
Molecular Formula C17H22I3N3O8
CAS Registry Number 60166-93-0
SMILES CC(C(=O)NC1=C(C(=C(C(=C1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Joint stiffness15.01.02.003--Not Available
Lacrimation disorder06.08.02.010--Not Available
Lacrimation increased06.08.02.0040.022763%
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.003--
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.034856%Not Available
Loss of consciousness17.02.04.0040.054773%Not Available
Malaise08.01.01.003--
Meningism17.02.05.007--
Meningitis aseptic17.06.03.002; 11.01.03.002--Not Available
Meningitis bacterial17.06.10.002; 11.02.01.013--Not Available
Menopausal symptoms21.02.02.002--Not Available
Muscle contractions involuntary17.05.03.001; 15.05.03.008--Not Available
Muscle spasms15.05.03.004--
Muscle spasticity17.05.03.007; 15.05.04.011--
Muscular weakness17.05.03.005; 15.05.06.0010.019206%
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myelitis17.06.02.001; 11.01.03.007--
Myelitis transverse17.06.02.002; 10.04.10.006--Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial ischaemia24.04.04.010; 02.02.02.008--Not Available
Nasal congestion22.04.04.0010.015649%
Nausea07.01.07.0010.142268%
Neck pain15.03.04.009--
Necrosis08.03.03.001; 24.04.02.006--Not Available
Nephropathy20.05.03.001--Not Available
Nephropathy toxic20.05.03.002; 12.03.01.0100.017783%Not Available
Nephrotic syndrome20.05.01.002--
Neuropathy peripheral17.09.03.003--Not Available
Neurotoxicity17.02.10.002; 12.03.01.0110.039124%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene